InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (17 ops.)
Insider track record
OtherDisclosed buys
0
Disclosed sells
17
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Versant Venture Capital VI, L.P.. Director active across 10 companies, notably LENZ Therapeutics, Inc.. In total, 28 reports have been recorded. Breakdown: 0 buy · 17 sells. Total volume traded: €57.7m. Activity tracked since 12 May 2021. The latest transaction was filed on 30 September 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Versant Venture Capital VI, L.P.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations28 total
49,701 shares@ US$45.35470.38% mcap36.6% of flowCommon StockSEC:0001193125-25-228493:0
2,370,533 shares@ US$1.401487.6% of flowCommon StockSEC:0001193125-25-213445:0
49,479 shares@ US$41.59085.5% of flowCommon StockSEC:0001193125-25-211363:0
307,707 shares@ US$1.533250.0% of flowCommon StockSEC:0001193125-25-207677:0
20,493 shares@ US$40.02970.14% mcap13.4% of flowCommon StockSEC:0000950170-25-111529:0
145,051 shares@ US$39.5016.5% of flowCommon StockSEC:0000950170-25-110163:0
191,376 shares@ US$34.0022.3% of flowCommon StockSEC:0000950170-25-095616:0
200,000 shares@ US$30.46527.0% of flowCommon StockSEC:0000950170-25-092373:0
100,000 shares@ US$29.9518.5% of flowCommon StockSEC:0000950170-25-088604:0
350,000 shares@ US$29.0077.2% of flowCommon StockSEC:0000950170-25-085490:0
89,990 shares@ US$9.65937.8% of flowCommon StockSEC:0000950170-24-119051:0
1,132,566 shares@ US$6.529663.8% of flowCommon StockSEC:0000950170-24-109112:0
541,897 shares@ US$6.0028.4% of flowCommon StockSEC:0000950170-24-106532:0
221,600 shares@ US$6.3202100.0% of flowCommon StockSEC:0000950170-24-102354:0
400,000 shares@ US$1.3501100.0% of flowCommon StockSEC:0000950170-24-095675:0
391,785 sharesClass A Common StockSEC:0000899243-24-000269:0
598,203 sharesCommon StockSEC:0000950170-24-035951:0
2,236,888 sharesCommon StockSEC:0000899243-23-000677:0
550,000 shares@ US$13.0302100.0% of flowCommon StockSEC:0000899243-22-028388:0
178,996 shares0Common StockSEC:0000899243-22-004169:0
200,213 shares0Common StockSEC:0000899243-22-001360:0
371,004 shares0Common StockSEC:0000899243-21-049938:0
200,213 shares0Common StockSEC:0000899243-21-049594:0
303,614 shares@ US$14.632750.0% of flowCommon StockSEC:0000899243-21-040777:0
12,343,727 sharesCommon StockSEC:0000899243-21-027018:0
25 of 28 declarations
About Versant Venture Capital VI, L.P.
Versant Venture Capital VI, L.P. is a declarant with 28 filings in total. Across the 28 sampled filings, all are sells, for sell volume of EUR 57742582, between 2021-05-14 and 2025-10-02. The companies involved include LENZ Therapeutics, Inc., Oyster Point Pharma, Inc., Monte Rosa Therapeutics, Inc., Century Therapeutics, Inc., LAVA Therapeutics NV, and Black Diamond Therapeutics, Inc.
